- Product Details
Keywords
- Anidulafungin
- 166663-25-8
- C58H73N7O17
Quick Details
- ProName: lower price Anidulafungin(166663-25-8...
- CasNo: 166663-25-8
- Molecular Formula: C58H73N7O17
- Appearance: white powder
- Application: used for research
- DeliveryTime: 3 days
- PackAge: aluminum foil bag
- Port: shenzhen
- ProductionCapacity: 1 Metric Ton/Day
- Purity: 99%min
- Storage: Store in cool, dry, ventilated place
- Transportation: by sea or by air
- LimitNum: 1 Gram
- Related Substances: N/A
- Residue on Ignition: N/A
- Heavy Metal: N/A
- Valid Period: one year
- N/A: N/A
Superiority
www.wolcase.com
Details
Anidulafungin is a semisynthetic echinocandin used as an antifungal drug. Anidulafungin was originally manufactured and submitted for FDA approval by Vicuron Pharmaceuticals.Pfizer acquired the drug upon its acquisition of Vicuron in the fall of 2005.Pfizer gained approval by the Food and Drug Administration (FDA) on February 21, 2006;it was previously known as LY303366. Preliminary evidence indicates it has a similar safety profile to caspofungin. Anidulafungin has proven efficacy against esophageal candidiasis, but its main use will probably be in invasive Candida infection;it may also have application in treating invasive Aspergillus infection. It is a member of the class of antifungal drugs known as the echinocandins; its mechanism of action is by inhibition of (1→3)-β-D-glucan synthase, an enzyme important to the synthesis of the fungal cell wall.
Anidulafungin is manufactured via semisynthesis. The starting material is echinocandin B (a lipopeptide fermentation product of Aspergillus nidulans or the closely related species, A. rugulosus), which undergoes deacylation (cleavage of the linoleoyl side chain) by the action of a deacylase enzyme from the bacterium Actinoplanes utahensis;in three subsequent synthetic steps, including a chemical reacylation, the antifungal drug anidulafungin is synthesized.Pharmacodynamics and pharmacokinetics[edit]Anidulafungin significantly differs from other antifungals in that it undergoes chemical degradation to inactive forms at body pH and temperature. Because it does not rely on enzymatic degradation or hepatic or renal excretion, the drug is safe to use in patients with any degree of hepatic or renal impairmentDistribution: 30–50 L. Protein binding: 84%.Anidulafungin is evidently metabolized by the liver. This specific drug undergoes slow chemical hydrolysis to an open-ring peptide which lacks antifungal activity. The half-life of the drug is 27 hours. Thirty percent is excreted in the feces (10% as unchanged drug). Less than 1% is excreted in the urine.Anidulafungin inhibits glucan synthase, an enzyme important in the formation of (1→3)-β-D-glucan, a major fungal cell wall component. Glucan synthase is not present in mammalian cells, so it is an attractive target for antifungal activity.How to use anidulafungin.Use anidulafungin as directed by your doctor. Check the label on the medicine for exact dosing instructions.Before using anidulafungin:
Some medical conditions may interact with anidulafungin. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
if you are pregnant, planning to become pregnant, or are breast-feeding
if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
if you have allergies to medicines, foods, or other substances
if you have a history of liver problems or abnormal liver function tests
Some MEDICINES MAY INTERACT with anidulafungin. However, no specific interactions with anidulafungin are known at this time.
Ask your health care provider if anidulafungin may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.